Volume 15, No 11, Nov 2005
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 15 Issue 11, November 2005: 962-969
REVIEWS
International NeuroAIDS: prospects of HIV-1 associated neurological complications
J Roberto TRUJILLO1, Gilberto JARAMILLO-RANGEL1, Marta ORTEGA-MARTINEZ1, Augusto C PENALVA de OLIVEIRA2,3, Jose E VIDAL2, Joseph BRYANT1 and Robert C GALLO1
1Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W Lombard Street, Baltimore, MD 21201, USA
2Institute of Infectious Diseases Emilio Ribas, Sao Paulo 01246, Brazil
3Clinical Research Unit in Human Retrovirology, University of Campinas, Sao Paulo 01246, Brazil
Correspondence: J Roberto TRUJILLO(Trujillo@umbi.umd.edu)
Neurological complications associated with HIV-1/AIDS are being recognized with a high frequency that parallels the increased number of AIDS cases. The early infiltration by HIV-1 into the nervous system can cause primary and/or secondary neurological complications. The most common neurocognitive disorder is AIDS Dementia Complex (ADC). In developing countries of Asia the three most opportunistic infections are tuberculosis (TB), cryptococcosis, and Pneumocystis carinii pneumonia. Therefore, it is expected that secondary neurological complications due to TB and cryptococcosis will be the most common cause of morbility and mortality in HIV-1/AIDS cases in China. Research of NeuroAIDS in China is necessary to understand the impact and the biology of HIV-1 in the nervous system. Future studies would include, the molecular epidemiology and the description of opportunistic infections associated to HIV-1; the neuropathological description of primary and secondary HIV-1 complications in different groups; the HIV-1 neurotropism and immune response studies for China's unique HIV-1 strains and recombinant forms derived from the nervous system, including experimental models such as the use of transgenic rats; and the study of potential resistant virus, primarily when the anti-retroviral therapy (ART) has not full access in the brain.
Cell Research (2005) 15, 962–969. doi:10.1038/sj.cr.7290374
FULL TEXT | PDF
Browse 2085
